[Pubmed] Psoriasis and Myasthenia Gravis: A Common Th-17 Pathway

[RSS-Bot]

Cureus. 2022 Mar 12;14(3):e23090. doi: 10.7759/cureus.23090. eCollection 2022 Mar.

ABSTRACT

Psoriasis is a chronic inflammatory skin disease whose treatment arsenal is expanding by the day. However, when comorbidities coexist, therapy can be challenging. We report a case of a 55-year-old female with steroid-dependent myasthenia gravis who presented with a severe form of chronic plaque psoriasis. After the failure of topical corticosteroids and phototherapy, the patient was started on ixekizumab. This anti-IL-17 antibody led not only to the clearance of the psoriatic lesions but also to the remission of the myasthenic symptoms. While on this medication, the patient was able to taper down and discontinue the oral corticosteroids. The remission of the symptoms of myasthenia gravis during this treatment supports the role of IL-17 cytokines in the pathogenesis of this disease and adds it as a management option in steroid-dependent cases.

PMID:35464501 | PMC:PMC8996433 | DOI:10.7759/cureus.23090


Source: https://pubmed.ncbi.nlm.nih.gov/3546450 ... 1&v=2.17.6